Peptide News: Retatrutide’s First Phase 3 Results Are In, and the Compounding Rulebook Still Isn’t Written

Two updates this week sit on opposite ends of the same story. Eli Lilly’s TRIUMPH-2 trial — the first full phase 3 dataset for retatrutide, the triple-hormone drug at the center of an ongoing federal court case — was presented at a major European diabetes conference and published in The Lancet, giving the clearest picture yet of what the drug actually does and doesn’t do. Meanwhile, on the regulatory side, trade press this week confirmed what we’ve suspected for months: the FDA’s own recommendation to legalize compounding for six other peptides has been sitting without action for two and a half months, even as the agency’s enforcement arm keeps sending warning letters to sellers who didn’t wait for permission.

Retatrutide’s First Full Phase 3 Trial Is Published — And It’s Not a Simple Story

On September 30, 2026, Eli Lilly presented results from TRIUMPH-2 (NCT05929079) at the European Association for the Study of Diabetes’s 62nd Annual Meeting in Milan, with simultaneous publication in The Lancet. It’s the first full phase 3 readout for retatrutide, the once-weekly GIP/GLP-1/glucagon triple agonist whose legal classification — drug or biologic — is the subject of the Seventh Circuit appeal we’ve been tracking.

The trial randomized 1,152 adults with obesity or overweight and type 2 diabetes to retatrutide 4 mg, 9 mg, 12 mg, or placebo over 80 weeks. At the 12 mg dose, average weight loss reached 20.8% (49.6 lbs), compared with 4.0% on placebo; A1C fell by an average of 1.5–1.6 percentage points across the active-dose arms, versus 0.2 on placebo. Just over half of patients on the 12 mg dose lost at least 20% of their body weight, and about 60% no longer met the clinical threshold for obesity by the end of the trial. The 12 mg arm also showed improvements in triglycerides, cholesterol, blood pressure, and a key inflammation marker.

The trial also reported its side-effect profile in detail, which matters as much as the efficacy numbers. Gastrointestinal effects were the most common adverse events — diarrhea in up to a third of patients on active treatment, nausea in up to 28%, and vomiting in up to 16%, compared with single-digit rates on placebo. Discontinuation due to side effects ranged from about 4% to 12% across the active-dose arms. Lilly’s principal investigator, Dr. Juan P. Frías, said the results “may change what we set out to achieve with a single therapy for adults living with type 2 diabetes and obesity.”

Why It Matters

This is the data that eventually has to support an FDA application — Lilly has said it plans to file a Biologics License Application in the first quarter of 2027. It’s also a useful corrective to how retatrutide gets talked about online, where gray-market sellers lean on the headline weight-loss number and leave out the discontinuation rates and GI side effects that showed up in a controlled, 1,152-person trial. None of this changes retatrutide’s legal status today: it remains in Phase 3 development, unapproved for any use, and anything sold under that name outside a clinical trial is being sold illegally — the same point we made when the Seventh Circuit heard oral argument on retatrutide’s classification last week, with no ruling yet.

The FDA’s Compounding Rulebook Is Still Stuck — Enforcement Isn’t Waiting

The second story is less a single event than a status check that trade press put plainly this week. Back in July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted to recommend six of seven nominated peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — for the legal 503A compounding list. As Pharmaceutical Executive reported on October 3, that recommendation is still sitting without formal HHS or FDA action more than two months later, while the agency’s enforcement division keeps moving: this is the same agency that sent Empower Pharmacy its third warning letter in September, and that cited five separate peptide sellers in August over products marketed for research use but sold for human injection.

That gap — an advisory recommendation stalled in the pipeline while enforcement proceeds against anyone who didn’t wait — is the core tension defining peptide access right now. Legal analysts have previously estimated that even once formal rulemaking begins, the process from proposed rule to final rule typically runs eight to twelve months. It hasn’t begun.

Where the Compounding Review Stands

The PCAC’s July recommendation for six peptides remains with HHS — no proposed rule, no published schedule. The separate, industry-driven EVEXIAS Life Sciences lawsuit against the FDA, challenging the agency’s restrictive “Category 2” listing of 17 peptides including BPC-157 and TB-500, is also still unresolved. And the Seventh Circuit has not ruled on retatrutide’s drug-versus-biologic classification since hearing oral argument on September 24 — appellate rulings on a case like this typically take weeks to months, and nothing published this week changes that estimate.

How to Read a New Trial’s Numbers Like a Physician Would

A trial like TRIUMPH-2 generates one headline number, but a physician reading the full dataset looks at more:

The placebo-adjusted effect, not the raw number. A 20.8% weight-loss figure means less without the 4.0% placebo result next to it.
Discontinuation due to side effects, not just the side-effect list. A drug with tolerable side effects is different from one people are actually stopping because of them.
Who was studied. This trial enrolled adults with type 2 diabetes and obesity specifically — a different population than someone using an unapproved version for general weight management.

Why This Matters If You’re Considering Peptide Therapy

Physician-guided only. Every treatment plan is reviewed and prescribed by an independent physician licensed in your state, and only when clinically appropriate — not approved by a product page.
Vetted, licensed U.S. pharmacies. We work with pharmacy partners held to accreditation-level standards, not just a baseline state license, and we track enforcement actions and legal status changes as closely as the trial data.
Care plans that adapt as regulation changes. Whether it’s the Seventh Circuit, HHS, or a new trial result, your plan follows what can be legally and safely prescribed and dispensed — not what a marketing page is selling this week.

FAQ

What did Lilly’s TRIUMPH-2 trial find about retatrutide?

In a 1,152-person phase 3 trial, adults with obesity and type 2 diabetes taking the 12 mg dose lost an average of 20.8% of body weight and 1.5 percentage points of A1C over 80 weeks, compared with 4.0% and 0.2 points on placebo. Gastrointestinal side effects, mainly diarrhea and nausea, were the most common adverse events, and 4–12% of patients on active treatment discontinued due to side effects.

Does this phase 3 data mean retatrutide is FDA-approved now?

No. Retatrutide remains an investigational drug in Phase 3 development. Lilly has said it plans to submit a Biologics License Application in the first quarter of 2027. Until the FDA approves a version, any retatrutide sold outside a clinical trial is being sold illegally.

What’s the status of the FDA’s plan to legalize compounding for six peptides?

Still stalled. The FDA’s Pharmacy Compounding Advisory Committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for the legal 503A compounding list in July 2026. As of this week, HHS has taken no formal action and no rulemaking has begun.

Did the Seventh Circuit rule on retatrutide’s legal classification?

Not yet. The court heard oral argument on September 24, 2026, and has not issued a decision. Appellate rulings in cases like this typically take weeks to months.

This article is for informational purposes only and does not constitute medical advice. Peptide therapy should only be pursued under the guidance of a licensed physician.

Retatrutide’s First Phase 3 Results Are In, and the Compounding Rulebook Still Isn’t Written